These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2715 related articles for article (PubMed ID: 31622696)

  • 41. Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans.
    Maccioni L; Gao B; Leclercq S; Pirlot B; Horsmans Y; De Timary P; Leclercq I; Fouts D; Schnabl B; Stärkel P
    Gut Microbes; 2020 Nov; 12(1):1782157. PubMed ID: 32588725
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
    Pierantonelli I; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
    Chen J; Thomsen M; Vitetta L
    J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Promises of microbiome-based therapies.
    Bajaj JS; Ng SC; Schnabl B
    J Hepatol; 2022 Jun; 76(6):1379-1391. PubMed ID: 35589257
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice.
    Hartmann P; Hochrath K; Horvath A; Chen P; Seebauer CT; Llorente C; Wang L; Alnouti Y; Fouts DE; Stärkel P; Loomba R; Coulter S; Liddle C; Yu RT; Ling L; Rossi SJ; DePaoli AM; Downes M; Evans RM; Brenner DA; Schnabl B
    Hepatology; 2018 Jun; 67(6):2150-2166. PubMed ID: 29159825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease.
    Filipovic B; Lukic S; Mijac D; Marjanovic-Haljilji M; Vojnovic M; Bogdanovic J; Glisic T; Filipovic N; Al Kiswani J; Djokovic A; Kapor S; Kapor S; Bukumiric Z; Starcevic A
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948020
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
    Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
    World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The role of gut microbiota in chronic liver diseases, and treatment possibilities].
    Hagymási K; Bacsárdi A; Egresi A; Berta E; Tulassay Z; Lengyel G
    Orv Hetil; 2018 Sep; 159(36):1465-1474. PubMed ID: 30175608
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gut Bacteria in Alcohol-Associated Liver Disease.
    Yang Y; Schnabl B
    Clin Liver Dis; 2024 Nov; 28(4):663-679. PubMed ID: 39362714
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice.
    Ferrere G; Wrzosek L; Cailleux F; Turpin W; Puchois V; Spatz M; Ciocan D; Rainteau D; Humbert L; Hugot C; Gaudin F; Noordine ML; Robert V; Berrebi D; Thomas M; Naveau S; Perlemuter G; Cassard AM
    J Hepatol; 2017 Apr; 66(4):806-815. PubMed ID: 27890791
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut-liver axis.
    Delzenne NM; Knudsen C; Beaumont M; Rodriguez J; Neyrinck AM; Bindels LB
    Proc Nutr Soc; 2019 Aug; 78(3):319-328. PubMed ID: 30628563
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage.
    Plaza-Díaz J; Solís-Urra P; Rodríguez-Rodríguez F; Olivares-Arancibia J; Navarro-Oliveros M; Abadía-Molina F; Álvarez-Mercado AI
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33171747
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation.
    Nicoletti A; Ponziani FR; Biolato M; Valenza V; Marrone G; Sganga G; Gasbarrini A; Miele L; Grieco A
    World J Gastroenterol; 2019 Sep; 25(33):4814-4834. PubMed ID: 31543676
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives.
    Arab JP; Arrese M; Shah VH
    Hepatol Res; 2020 Apr; 50(4):407-418. PubMed ID: 31840358
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The gut microbiota-bile acid axis in cholestatic liver disease.
    Sun D; Xie C; Zhao Y; Liao J; Li S; Zhang Y; Wang D; Hua K; Gu Y; Du J; Huang G; Huang J
    Mol Med; 2024 Jul; 30(1):104. PubMed ID: 39030473
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Deciphering the role of gut metabolites in non-alcoholic fatty liver disease.
    Ralli T; Saifi Z; Tyagi N; Vidyadhari A; Aeri V; Kohli K
    Crit Rev Microbiol; 2023 Nov; 49(6):815-833. PubMed ID: 36394607
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gut microbiota and metabolites of cirrhotic portal hypertension: a novel target on the therapeutic regulation.
    Hao Y; Hao Z; Zeng X; Lin Y
    J Gastroenterol; 2024 Sep; 59(9):788-797. PubMed ID: 39028343
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gut microbiome as a therapeutic target for liver diseases.
    Singh TP; Kadyan S; Devi H; Park G; Nagpal R
    Life Sci; 2023 Jun; 322():121685. PubMed ID: 37044173
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gut Microbes in Polycystic Ovary Syndrome and Associated Comorbidities; Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease (NAFLD), Cardiovascular Disease (CVD), and the Potential of Microbial Therapeutics.
    Singh V; Mahra K; Jung D; Shin JH
    Probiotics Antimicrob Proteins; 2024 Oct; 16(5):1744-1761. PubMed ID: 38647957
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease Progression.
    Mungamuri SK; Vijayasarathy K
    Crit Rev Oncog; 2020; 25(1):57-70. PubMed ID: 32865911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 136.